Satavaptan
Satavaptan is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target vasopressin V1a receptor, vasopressin V2 receptor, and vasopressin V1b receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
11 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 3 | 3 | — | — | 6 |
| Ascites | D001201 | — | R18 | — | 3 | 3 | — | — | 6 |
| Hyponatremia | D007010 | — | E87.1 | — | 1 | 4 | — | — | 5 |
| Syndrome | D013577 | — | — | — | 1 | 3 | — | — | 4 |
| Inappropriate adh syndrome | D007177 | EFO_1000982 | E22.2 | — | 1 | 3 | — | — | 4 |
| Fibrosis | D005355 | — | — | — | — | 3 | — | — | 3 |
| Diabetes insipidus | D003919 | — | E23.2 | — | 1 | 2 | — | — | 3 |
| Recurrence | D012008 | — | — | — | — | 2 | — | — | 2 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Satavaptan |
| INN | satavaptan |
| Description | Satavaptan (INN; developmental code name SR121463, former tentative brand name Aquilda) is a vasopressin-2 receptor antagonist which was investigation by Sanofi-Aventis and was under development for the treatment of hyponatremia. It was also being studied for the treatment of ascites. Development was discontinued in 2009.
|
| Classification | Small molecule |
| Drug class | aptamers, classical and mirror; vasopressin receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCOc1ccc2c(c1)[C@]1(CC[C@H](CCN3CCOCC3)CC1)C(=O)N2S(=O)(=O)c1ccc(C(=O)NC(C)(C)C)cc1OC |
Identifiers
| PDB | — |
| CAS-ID | 185913-78-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2107777 |
| ChEBI ID | — |
| PubChem CID | 9810773 |
| DrugBank | DB14923 |
| UNII ID | AJS8S3P31H (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
AVPR1A
AVPR1A
AVPR2
AVPR2
AVPR1B
AVPR1B
Organism
Homo sapiens
Gene name
AVPR1A
Gene synonyms
AVPR1
NCBI Gene ID
Protein name
vasopressin V1a receptor
Protein synonyms
Antidiuretic hormone receptor 1a, AVPR V1a, SCCL vasopressin subtype 1a receptor, V1-vascular vasopressin receptor AVPR1A, V1a vasopressin receptor, Vascular/hepatic-type arginine vasopressin receptor
Uniprot ID
Mouse ortholog
Avpr1a (54140)
vasopressin V1a receptor (Q9QYH2)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 272 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use